Adamis Pharmaceuticals (NASDAQ:ADMP) Now Covered by StockNews.com

StockNews.com started coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMPGet Rating) in a report issued on Sunday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

ADMP opened at $0.41 on Friday. The firm has a fifty day moving average price of $0.49 and a 200 day moving average price of $0.62. Adamis Pharmaceuticals has a 1 year low of $0.31 and a 1 year high of $1.48.

Adamis Pharmaceuticals (NASDAQ:ADMPGet Rating) last issued its quarterly earnings results on Monday, May 16th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.04). Adamis Pharmaceuticals had a negative return on equity of 100.63% and a negative net margin of 458.77%. As a group, equities research analysts forecast that Adamis Pharmaceuticals will post -0.15 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC lifted its position in shares of Adamis Pharmaceuticals by 3,449.4% during the third quarter. Millennium Management LLC now owns 557,157 shares of the specialty pharmaceutical company’s stock worth $540,000 after purchasing an additional 541,460 shares in the last quarter. State Street Corp increased its stake in Adamis Pharmaceuticals by 13.1% in the first quarter. State Street Corp now owns 475,373 shares of the specialty pharmaceutical company’s stock valued at $271,000 after purchasing an additional 55,168 shares during the last quarter. Virtu Financial LLC increased its stake in Adamis Pharmaceuticals by 9.6% in the fourth quarter. Virtu Financial LLC now owns 224,561 shares of the specialty pharmaceutical company’s stock valued at $136,000 after purchasing an additional 19,691 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Adamis Pharmaceuticals by 735.2% in the fourth quarter. JPMorgan Chase & Co. now owns 218,573 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 192,403 shares during the last quarter. Finally, Capital CS Group LLC purchased a new position in Adamis Pharmaceuticals in the first quarter valued at approximately $40,000. 9.52% of the stock is currently owned by institutional investors.

About Adamis Pharmaceuticals (Get Rating)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.